This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Korea Institute of Radiological & Medical Sciences. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
**Title: Gil-Hong Park: Innovator in Cancer Treatment**
Introduction
Gil-Hong Park is a prominent inventor based in Seoul, South Korea. He holds a significant patent that paves the way for advancements in pharmaceutical treatments for malignant tumors. His work has the potential to revolutionize cancer gene therapy, contributing to the fight against one of the most critical health challenges today.
Latest Patents
Gil-Hong Park's notable patent is titled "Pharmaceutical composition for treating malignant tumors containing human p31 genes." This innovative pharmaceutical composition comprises a human p31 gene encoding protein, represented by SEQ ID NO: 3 or 4, as its effective component. This composition has demonstrated the ability to suppress cancer cell growth, induce apoptosis, and kill cells by overexpressing p31 in solid malignant tumor cells. Consequently, this innovative approach can be effectively utilized for gene therapy in cancer treatment.
Career Highlights
Gil-Hong Park is associated with the Korea Institute of Radiological & Medical Sciences. His background in this leading research institution has provided him with the platform to develop novel solutions addressing critical health issues. His patent reflects his comprehensive research and dedication to improving medical treatments, particularly in oncology.
Collaborations
While working at the Korea Institute of Radiological & Medical Sciences, Gil-Hong Park has collaborated with esteemed colleagues, including Kee-Ho Lee and Sang-Hoon Kim. These collaborations emphasize the importance of teamwork in research and innovation, as they strive toward common goals in the medical field.
Conclusion
Gil-Hong Park's contributions to cancer treatment through his unique patented pharmaceutical composition highlight his innovative spirit and commitment to healthcare improvement. His work not only showcases individual brilliance but also the collaborative effort within the research community, paving the way for future advancements in medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile